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An Hut-78 cell clone (F12) harboring a nonproducer human immunodeficiency virus-1 (HIV) variant, and showing a complete 
resistance to HIV-1 or HIV-2 superinfection, was previously characterized. We demonstrated that the replication of the 
superinfecting HIVs is blocked at the retrotranecription step, despite the CD4 down-regulation, since HIVe are able to cross 
the Hut-78/F12 cell membrane. In order to establish if the expression of the HIV-1 variant (F12/HIV) could be per se 
sufficient to induce the homologous viral interference shown in the F12 cells, the whole F12/HIV provirus was cloned and 
transfected in He-La CD4+ cells. In F12/HIV expressing He-La CD4+ clones, both the viral proteins expressed and the 
HIV nonproducer phenotype remain unmodified compared to F12 cells. Furthermore, despite the full expression of CD4 
HIV receptors, the life cycle of the superinfecting HIV could be either strongly inl-]ibited or totally abolished, depending on 
the cell clone considered. The inhibition of the euperinfecting HIV was also reproduced when an HIV infectious molecular 
clone was transfected in F12/HIV He-La CD4+ clones, thus indicating that a post-cDNA synthesis block may operate against 
the superinfecting HIV. These data demonstrate that HIV susceptibility could be abrogated in cells expressing the F12/HIV 
genome, even in absence of any CD4 down-regulation. © 1995 Academic Press, Inc. 
INTRODUCTION 
Over the past few years different experimental strate- 
gies have been developed in the fight against human 
immunodeficiency virus (HIV) infection. Among these, the 
block of HIV infection generated by the expression of a 
dominant-negative mutant allele of an HIV viral protein 
was demonstrated and first reported in Trono et al. 
(1989); cells harboring a gag-mutated defective HIV-1 
provirus exhibited either greatly reduced yields or no 
replication of superinfected HIV. The expression of other 
structural or regulatory HIV genes (i.e., env, tat, rev), ei- 
ther in the "wild" or in mutated forms, has also been 
demonstrated to interfere with the HIV life cycle (for a 
review see Yu et aL, 1994). More recently, anti-HIV intra- 
cellular immunization was achieved with the use of TAR 
(Sullenger eta/., 1990) or RRE (Lee eta/., 1992) decoys, 
or with the expression of anti-HIV ribozymes (SaGer et 
a/., 1990). Clinical trials based on the anti-HIV action of 
either a mutated rev protein (M10) (Malim eta/., 1992) or 
an HIV-LTR leader sequence-directed ribozyme (Yamada 
eta/., 1994) have been approved. Hence, intracellular 
immunization induced by the expression of a nonpro- 
ducer HIV-1 genome may represent a tool for a "gene 
therapy" approach to the treatment of AIDS. 
An infected, nonproducer and CD4 down-regulated 
Hut-78 cell clone (F12), bearing an HIV-1 variant with no 
major genomic changes, has been described (Federico 
et aL, 1989). While F12/HIV-1 provirus is well expressed, 
the pattern of viral protein is altered with respect to repli- 
cation competent HIV. Nonproducer F12 cells are fully 
resistant to HIV-1 or HIV-2 superinfection, even at high 
multiplicity of infection (m.o.i.). 2 This homologous viral 
interference appears to be mediated by a block in the 
retrotranscription of the first DNA strand of superinfecting 
HlVs (Taddeo et aL, 1993). The possibility, however, that 
the F12/HIV viral phenotype (i.e., the nonproductivity and, 
more interestingly, the homologous interference) also de- 
pends on the host cell clone was not completely ex- 
cluded. 
In this paper, we report data obtained in neoresistant 
He-La CD4+ human cells cotransfected with the F12/HIV 
full-length molecular clone (whose complete sequencing 
demonstrated the absence of genetic deletions) (Carlini 
et al., 1992) and with the p220.2 plasmid 'carrying the 
hygromycin B (Hyg. B) resistance gene. As expected, the 
typical F12/HIV nonproducer viral phenotype was repro- 
duced in the He-La CD4+ cells. In addition, as the 
transfected He-La clones remain CD4-1- while F12 cells 
are CD4 down-regulated, the former represent a more 
efficient cell system for testing whether HIV susceptibility 
could be abrogated in cells expressing the F12/HIV ge- 
nome. Upon HIV-t challenge of F12/HIV-transfected He- 
La CD4+ clones, either the block or a strong inhibition 
of virus yield was detected depending on the cell clone 
analyzed and the postinfection (p.i.) time considered. 
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As for the mechanism of action, the intracellular immu- 
nization of the F12/HIV He-La CD4+-transfected clones 
against HIV-1 appears to be controlled at a step(s) distal 
to the retrotranscription of superinfecting HIV. 
MATERIALS AND METHODS 
Cell cultures, virus superinfection, and detection 
He-La, He-La CD4+ cells, and F12/HIV-transfected 
He-La CD4+ clones were grown in Dulbecco's modified 
Eagle medium (Flow Laboratories, Scotland) supple- 
mented with 10% fetal calf serum (FCS) and 0.5 mg/ml 
Geneticine-(neo) (except He-La cells) and split biweekly. 
All Hyg. B-resistant He-La CD4+ clones were maintained 
in 0.2 mg/ml neo plus 0.2 mg/ml Hyg. B (Sigma, St. Louis, 
M0). CEMss cells, 8E5 (Folks eta/., 1986), H9/HTLV-IIIB 
(RatneretaL, 1985), C8166, CEM x 174, MT-2, and F12 
cells were grown in RPMI 1640 medium (Flow Labora- 
tories) supplemented with 10% FCS, and split biweekly. 
Reverse transcriptase (RT) assay was performed as 
previously described (Rossi eta/., 1987; Titti et aL, 1992). 
HIV-1 and -2 TCIDso titers were determined by infecting 
C8166 cells with 10-fold serial dilutions of the viral prepa- 
rations (except for the back titration experiments where 
twofold serial dilutions were assayed) and by measuring 
the cytopathic effect (syncytia formation, 5 days p.i.). All 
virus stocks were made DNA-free by treatment with 
DNase as in Taddeo eta/. (1993) prior to cell infection. 
Cotransfection 
Transfection experiments were performed using the 
calcium-phosphate coprecipitation method (Wigler et 
al., 1979). Cotransfection was carried out by adding 2/~g 
0ffull-length molecular clone F12/HIV (carried by a pUc 
19 vector)(Carlini eta/., 1992) and 0.2 #g p220.2 plasmids 
(carrying the Hyg. B resistance gene) (Hauer eta/., 1989) 
to 2 X 106 He-La CD4+ cells in 10-cm dishes. He-La 
CD4÷ cells transfected with the p220.2 plasmid alone 
(i.e., clone P2) served as a control, as this ptasmid con- 
tains the whole sequence of pUc plasmid. Cells were 
cloned 2 days after transfection by the limiting-dilution 
method in 96-well plates in the presence of Hyg. B and 
ne0 (both at 0.2 mg/ml). 
FACS analysis 
OD4 receptors on the plasma membrane were de- 
tected by indirect immunofluorescence analyzed by a 
cytofluorometer, as described in Taddeo et al. (1993). 
Briefly, 106 cells were incubated with the appropriate 
concentration of the anti-CD4 monoclonal antibody (Or- 
th0 Diagnostic, Raritan, N J) in 100 #1 of phosphate-buf- 
fered saline (PBS) containing 2.6% FCS. After an incuba- 
tion of 60 min in ice, samples were washed twice in PBS 
and further incubated for 60 min in ice with 100 #1 of 
1,20 goat anti-mouse IgG conjugated with fluorescein 
is0thiocyanate (Ortho Diagnostic). After two washes with 
PBS, samples were fixed with 3% volume of formaldehyde 
and analyzed by a cytofluorometer (FAC-scan, Becton- 
Dickinson, Mountain View, CA). 
Nucleic acid analysis 
Southern and Northern blot analyses were performed 
as in Federico eta/. (1989). Proviral DNA copies/cell were 
enumerated via Southern blotting of Hindlll-restricted 
high molecular weight DNA of F12/HIV He-La CD4+ and 
of 8E5 cells as the latter are known to contain one copy/ 
cell of HIV-1 proviral DNA. 
PCR amplification of infected cell lysates 
DNA for PER amplification experiments was prepared 
as follows. Cells were washed twice in PBS and then 
lysed in tridistilled, water for 10 min at 95 °. Proteins were 
digested with proteinase K (200 #g/ml) at 55 ° for 30 min. 
The enzyme was then inactivated at 95 ° for 10 min, and 
total cell lysates resulting from this procedure were used 
for PCR amplification. 
All reagents used were specifically prepared for PCR 
and were proven to be free of contamination with HIV-1 
or HIV-2 DNA by DNA-PCR. DNA-PCR amplification was 
performed as follows. Each reaction mixture was 25 #1 
in volume and contained 10 #1 of total cell lysates or 100 
ng of high molecular weight DNA (see above), 150 ng of 
each otigonucleotide primer, 0.2 mM each of the four 
deoxynucleotide triphosphates, 10 mM Tris-HCI (pH 
8.3), 1.5 mM MgCI2, 0.01% (wt/vol) gelatin, and 1 unit of 
Taq DNA polymerase (Perkin-Elmer Corp., Norwalk, CT). 
Amplification was carried out in a Perkin-EImer ther- 
mocycler for 35 cycles, with 1 min of denaturation at 95 °, 
1 min of annealing at 55 ° , and 2 min of extension at 72 ° . 
Amplified products were analyzed by eleotrophoresis on 
1.8% agarose gel, transferred to a nylon filter (Hybond- 
N-Amersham), and hybridized at 42 ° with a 32p-labeled 
specific oligonucleotide. Filters were washed for at least 
1 hr at 42 ° in 2X SSPE (1X SSPE: 0.18 M NaCI, 0.01 M 
NaH2PO4, pH 7.4, 0.001 M EDTA, pH 7.4), 0.1% sodium 
dodecyl sulfate, and exposed for 24 hr in a Kodak cas- 
sette. 
The nucleotide sequences of the oligonucleotide prim- 
ers used for DNA detection were derived from the nucleo- 
tide sequences of F12/HIV (Carlini et al., 1992), HIV-1 
HXB2 strain (Ratner eta/., 1985), HIV-1 pNL4-3 infectious 
molecular clone (Adachi et aL, 1986), and of HIV-2ROD 
(Guyader et aL, 1987). 
Protein detection 
The determination of intracellular p24 antigen in 
transfected He-La CD4+ clones was carried out by the 
Antigen Capture assay (Abbott, North Chicago, IL). HIV- 
related proteins were detected by a radioimmunoprecipi- 
tation assay (RIPA) performed as in Federico eta/. (1989). 
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FIG. 2. Twenty micrograms of total RNA extracted from He-La OD4+ 
clone P2 transfected with p220.2 vector, F12 cells, and six F12/HIV He- 
La CD4+ clones was analyzed by Northern blot and hybridized with 
the same probe (F12/HIV) as in Fig. 1. On the left, kb corresponding 
to the major signals are indicated. 
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FIG. 1. (I) Equal amounts (30 #g) of DNA from four different F12/HIV 
He-La CD4+ clones (6, 9, 10, 15) were Hindlll digested, Southern 
blotted, and hybridized with the full-length F12/HIV probe. DNA from 
F12 cells (Federico et aL, 1989) was used as a positive control. On 
the left, kbp corresponding to the band size of lambda phage Hindlll- 
digested DNA are indicated. (lla) The 1.6-kbp signals from Hindlll DNA 
of clones 6, 9, F12, and 8E5 hybridized with the full-length F12/HIV 
probe are shown. DNA of clone P2 was used as a negative control. 
(lib) The same filter was rehybridized with the probe for the human 
coagulation factor IX(exon VIII) and signals from both autoradiograph- 
ies were scanned in an Ultra Scan Beckman. HIV/Hindlll bands were 
compared to that of 8E5 cells, a clone containing a single copy of HIV 
(Folks et aL, 1986). 
RESU LTS 
Character izat ion of He-La CD4+ clones cotransfected 
with the F12/HIV molecular  c lone and the p220.2 
plasmid 
A molecular characterization was first performed by 
comparing parental F12 and He-La CD4+ cell clones 
transfected with the full-length molecular clone of the 
nonproducer HIV-1 variant cloned out from the F12 cells. 
Southern blot analysis of high molecular weight DNA 
from selected He-La CD4+ clones cotransfected with 
F12/HIV-pUc and p220.2 plasmids shows the presence 
of approximately 10- to 15-fold more copies/cell  of F12/ 
HIV DNA than in F12 cells. The data in Fig. 1 indicate 
that F12/HIVtransfected He-La CD4+ clones contain ap- 
proximately 20 copies/cel l  of proviral DNA whi le F12 cells 
contain approximately 2 copies/cell. The Hind l l l  pattern 
of He-La CD4+ clones shown here is consistent with 
the sequence data of F12/HIV genome already reported 
(Carlini eta/ . ,  1992)(Accession No. Z11530). The integra- 
tion of F12/HIV proviral DNA remains stable for >1 year 
when transfected clones are kept in antibiotic supple- 
mented cultures (not shown). 
Northern blotting of RNA from F12/HIV expressing He- 
La CD4+ clones shows a transcriptional activity compa- 
rable to those of F12 cells (representative examples of 
six clones are shown in Fig. 2). However, in the F12 
cells, the 1.8- to 2.0-kb band (coding for HIV regulatory 
proteins) is more expressed than in any of the transfected 
clones. 
RIPA assay indicates that, as in F12 ceils, only the 
uncleaved form of the gp160 env glycoprotein is present 
in all clones tested. Reduced amounts of the gag proteins 
are present as well (Fig. 3). The exclusive presence of 
uncleaved gp160 was also demonstrated in a RIPA assay 
using a gp160-specific polyclonal antibody (Fig. 4). 
Finally, in order to demonstrate that F12/HIV He-La 
CD4+ clones, like parental F12 cells, did not release HIV 
infectious virions, CEMss cells were added to cultures 
of each of 10 clones to amplify possibly released infec- 
tious HIV particles. Even after 25 days of coculture, no 
formation of syncytia or RT was detected in the superna- 
tants (data not shown). 
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FIG. 3. RIPA assay of representative F12/HIV e-La CD4+ clones 
performed with either a mixture of HIV positive patients' era (-I-) or 
HIV negative donors' era (-). Lysates from F12 and H9/HTLV-IIIB cells 
were used as controls. ~4C-[abeled molecular markers (Amersham) and 
HIV proteins detectable in RIPA are also marked. 
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He-La CD4+ clones considered, irrespective of the ex- 
pression of the F12/HIV genome. 
200 
97 
69  
gp 160 
gp 120 
4" -- -!- -I" 
FIG. 4. RIPA assay of F12/HIV He-La CD4+ clone 6. A rabbit anti- 
HIV gp160 polyclonal serum was added to the cell lysates (lanes +). 
As a control, radiolabeled lysate from H9/HTLV-IIIB cells was reacted 
with an HIV negative donor serum (-). 14C-labeled molecular markers 
are indicated on the left. 
CD4 receptor expression 
A crucial point in the study of viral interference is the 
modulation of viral receptors. As already mentioned, pa- 
rental F12 cells are totally deprived of HIV membrane 
receptors (Taddeo et al., 1993). In chronically HIV-in- 
fected cells, the phenomenon of CD4 down-regulation is 
highly reproducible, except in very few cases (Le Guern 
and Levy, 1992). Although entry of the superinfecting vi- 
rus was demonstrated (Federico et aL, 1991; Luciani et 
a/., 1991; Maggiorella et al., 1992; Taddeo et aL, 1993), 
contribution of CD4 down-regulation in the homologous 
interference in F12 cells could be hypothesized in terms 
of lower efficacy of viral entry. Thus, in order to verify 
the efficacy of F12/HIV expression in inducing anti-HIV 
intracellular immunization, the isolation of non-OD4 
d0wn-regulated cell clones expressing the typical F12/ 
HlVviral phenotype could be of great interest. 
FA0S analysis performed using OKT4A monoclonal 
antibodies demonstrates that no significant variations in 
the CD4 receptor exposure are detectable in any F12/ 
HIV expressing He-La CD4+ clones. The clones were 
tested with respect to both parental He-La CD4-1- cells 
andthe He-La CD4+ clone that was transfected with the 
ptasmid carrying only the Hygromycin B resistance 
gene (P2). 
Figure 5 shows the FACS analysis of representative 
clones; in particular, the slight decrease in the fluores- 
cence intensity with respect to the parental He-La OD4+ 
cells that could be detected in clones 6 and 9 is also 
present in the fully H IV susceptible P2 clone. Conversely, 
the clone 10 (another HIV resistant clone) FACS slope is 
identical to that of He-La CD4+ cells. All cell clone values 
are over 90% CD4 positive, as in parental cells. Therefore, 
we can realistically hypothesize that the HIVvirions could 
HIV-1 challenge of F12/HIV He-La CD4+ clones 
The ultimate goal of our experimental approach was to 
assess if expression of the F12/HIV could per se induce 
protection from HIV-1 superinfection in the host cell. 
Thus, 10 He-La CD4+ cell clones highly expressing the 
F12/HIV genome were superinfected with the HTLV-ilIB 
strain of HIV-1 (superimposable results were also ob- 
tained superinfecting with the NL4-3 HIV-1 strain, not 
shown) at a multiplicity of 1.7 X 103 TCIDso/106 cells. As 
a control, a cell clone (P2) containing plasmid carrying 
only the Hygromycin B resistance gene was used, since 
it was demonstrated that HIV can replicate in it as well 
as in parental He-.La CD4+ cells (not shown). 
In the supernatants of 7 of 10 clones, no RT activity 
could be detected at any time, whereas in the remaining 
3 cell clones the RTvalues are at times above the back- 
ground (Fig. 6). 
Two cell clones (clone 6 and 9) representative of the 
former group were superinfected at different m.o.i. As 
expected, in lowering the m.o.i. (3.4 x 102 TCIDsc/106 
cells) both clones remain fully HIV resistant. At an in- 
creased m.o.i, clone 9 still resists HIV superinfection 
whereas the resistance of clone 6 was partially overcome 
when a m.o.i, of 1.7 X 104 TOlDso/106 cells was utilized 
(Table 1 ). 
Mechanism of action of the F12/HIV-induced 
homologous viral interference. 
Retrotranscripdon of superinfecting H/V is not inhibited 
in F12/H/V He-La CD4+ c/ones. As previously described 
(Taddeo et aL, 1993), intracellular resistance to superin- 
fection with HIV-2 (whose sequences in the LTR-gag- 
primer binding site regions are divergent enough from 
the endogenous F12/HIV to allow discriminating DNA- 
PCR analysis) appears to be mediated in F12 cells by a 
block of the complete cDNA retrotranscription. To verify 
if a superimposable phenomenon could take place in 
F12/HIV expressing He-La CD4+ clones, clones 6 and 
9, control P2 clone, as well as F12 cells were exposed 
to 1.7 X 103 TCIDs0/106 cells of HIV-2ROD. At 8 hr p.i., 
lysates from 10-fold serially diluted superinfected cells 
were assayed for DNA-PCR employing primers ampli- 
fying either the primer binding site regions where retro- 
transcription ends (Taddeo et aL, 1993) or the fl-globin 
gene. Data shown in Fig. 7(iv) indicate that the DNA-PCR 
was fully negative in F12 cells, whereas it was positive 
in clones P2, 6, and 9 (Figs. 7(i), 7(ii), and 7(iii)). Moreover, 
no quantitatively reduced amounts of LTR-gag DNA prod- 
ucts were detected in HIV-2 superinfected clones 6 or 9 
compared to the control P2 clone. On the contrary, the 
scanning analysis (see the legend to Fig. 7) indicates 
that the DNA-PCR signals from samples of superinfected 
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Fie. 5. CD4 FACS analysis. F12/HIV He-La CD4+ clones 6 (94.2% CD4+), 9 (95.2%), and 10 (95.8%) are shown. Controls consist of clone P2 
(96.2%) transfected with p220.2 plasmid only, He-La (negative control, <1%) and untreated parental He-La OD4+ (positive control, 99.2%) cells. 
clones 6 and 9 (normalized with the fl-globin signals) are 
two- to fivefold stronger than those from the correspond- 
ing superinfected P2 clone samples. In addition, the dis- 
appearance of the signal at the same cell dilution among 
different clones suggests that the number of cells where 
HIV-2 full retrotranscription occurs does not seem to vary 
significantly among the control and the F12/HIV He-La 
CD4+ clones. These data indicate that the superinfecting 
HIV-2 is able to complete its retrotranscription in F12/ 
HIV He-La CD4+ clones at a quantitatively similar (per- 
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FiG. 6. HIV superinfection. Clarified supernatants from H9/HTLV-IIIs 
cells were used at 1.7 X 109 TCID~o/10 ~ cells to superinfect F12/HIV 
He-La CD4÷ clones (0.1 ml virus was added to 50,000 cells in 24-well 
plates, 1-hr adsorption at 37 ° , and then 1 ml of medium was added). 
At different days p.i, supematants of superinfected F12/HIV He-La 
CD4+ clones were tested for RT activity. RT values are given as cpm/ 
ml of culture supernatant. (I), P2 clone. 
haps even higher) level with respect to the He-La CD4+ 
control clone but not, as already assessed, in F12 cells. 
For unknown reasons, however, HIV-2ROD rep}icates very 
poorly in He-La CD4+ cells, thus hindering the possibifity 
of assessing if F12/HIV He-La CD4+ clones could als0 
be protected in regards to HIV-2 superinfection. 
Similar DNA-PCR positivity was obtained (by using 
primers able to discriminate between HTLV-IIIB and F12/ 
HIV genomes- -see the legend to Fig. 8) amplifying df 
sequences of the same He-La CD4+ clone cell lysates 
analyzed shortly after the HIV-1 superinfection (data not 
shown). 
No DNA of superinfecting HIV was detectable in the 
"immunized" F12/HIV He-La CD4+ clones 12 days p,L 
The demonstrated ability of the superinfecting HIV to 
fully retrotranscribe its genomic RNA in F12/HIV He- 
La CD4+ clones proposes the question regarding the 
fate of this cDNA in cell cultures fully protected from 
superinfection. DNA-PCR experiments performed us- 
ing HTLV-III~ specific vifprimers in cell lysates 12 days 
after superinfection show a lack of HTLV-IIIB cDNA in 
the protected clone 9 at the higher m.o.i. (see above), 
whereas, as expected, partially protected clone 6 cell 
lysates are DNA-POR positive (Fig. 8), It is therefore 
evident that the retrotranscribed cDNA disappeared in 
the protected F12/HIV He-La Oh4+ cultures, possibly 
due either to a selective death of cells where the retro- 
transcription occurs (without any detectable virus re- 
lease) or to the intracellular degradation of the superin- 
fecting HIV cDNA. 
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TABLE 1 
RT VALUES a IN THE SUPERNATANTS OF HtV-1-SUPERINFECTED CULTURES OF F12/HIV He-La CD4+ CLONES 6 AND 9 AND OF CONTROL P2 CLONE 
81 
Days 
p.i. 
m.o.i. 3.4 x 10 2 m.o,i. 1.7 X 10 3 m.o.i. 6.8 X 10 3 m.o.i. 1,7 X 10 4 
P2 6 9 P2 6 9 P2 6 9 P2 6 9 
7 8.6 2.8 1.7 2.3 5.4 2.1 12.4 8.2 2.9 231.0 63.0 5.2 
10 n.t. 3.0 2.2 1.9 2.4 1.1 304.3 3.5 2.0 273.3 12.0 4.7 
12 n.t. n.t. n.t. n.t. n.t. n.t. 668.0 4.7 0.7 348.1 48.3 2.3 
17 28.0 8.7 8.2 422.1 7.3 4.1 404.2 15.9 23.4 521.8 190.1 20.8 
21 355.9 24.1 13.5 637.8 • 23.6 8.1 504.3 10.3 21.6 721.1 89.3 8.5 
24 449.2 5.2 9.4 266.3 6.3 8.2 698.7 6.0 6.9 643.7 19.0 6.9 
28 103.8 10.2 28.5 380.7 23.8 12.4 370.2 2.8 2.5 278.1 297.6 4.2 
31 104.4 2.6 8.6 522•1 6.6 5.0 n.t. n.t. n.t. n.t. n.t. n.t. 
cpm/ml X 10 -3 after background subtraction. 
F12/HIV He-La CL)4+ display intracellular immuniza- 
tion also when transfected with the pNL4-3 H/V-1 infec- 
tious molecular clone. F12/HIV He-La CD4+ clones 6, 9, 
and control P2 clone were transfected with either 10 or 
50/~g/106 cells of the HIV-1 infectious molecular clone 
pNL4-3. The kinetics of virus release in the supernatant 
were measured by RT values and HIV back-titration in 
08166 cells. In Table 2, the results of transfection with 
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FIG. 7. DNA-PCR of HIV-2 superinfected cell clones. Eight hours after 
HIV-2 superinfection (see Results), lysates from 6 X 104 uninfected (a) 
and from 5 X 10 4 (b), 5 X 10 s (c), 5 x 10 z (d), 5 X 10 ~ (e), and 5 x 100 
{f) HIV-2-superinfected cells of clones P2 (i), 6 (ii), and 9 (iii) were 
prepared as described under Materials and Methods. Each sample 
was amplified using either HIV-2 specific primers able to amplify only 
a fully retrotranscribed viral cDNA (Taddeo et al., 1993) (top, 16 hr of 
exposition) or fl-globin specific primers (Saiki eta/.,  1985)(bottom, 3 
mr of exposition). DNA-PCR mixture control (g) and the amplification 
products from 5 x 104 of either HIV-2-superinfected F12 (h) or HIV-2 
chronically infected CEMss (i) cells, using either HIV-2 (top) or/3-globin 
(bottom) specific primers, are shown in (iv) (3 hr of exposition)• After 
48 hr of exposition the results are not qualitatively modified• The DNA- 
P0R signals were scanned utilizing Phospho-lmager (Packard-Instru- 
ments, Meriden, CT) software and the relative intensities were ex- 
pressed in cpm. Values obtained for the HIV-2 amplified products, after 
the normalization of values for clones 6 and 9 comparing the respective 
~-globin signals to those of clone P2, are= clone P2 (b) 1010, (c) 237; 
clone 6 (b) 2253, (c) 625; clone 9 (b) 3012, (c) 1185. 
50 #g of pNL4-3, are reported; the data concerning the 
10-#g transfection are superimposable (not shown). In 
supernatants from clones 6 and 9, RT values >10-fold 
higher than the background values (cpm 902 + 237, 
mean + standard deviation) were occasionally detected 
(at 60 and 96 hr for clone 6 and at 96 hr for clone 9). 
However, these samples were fully negative when as- 
sayed, even undiluted, in twofold serial dilution back- 
titration experiments on C8166 cells. When CEMss cells 
were added up to 2 days after transfection, the formation 
of syncytia was observed. No syncytia were formed if 
the coculture with CEMss cells was started 4 days after 
transfection. These data seem to indicate that also when 
an infectious cDNA was used as a challenging virus 
there is not a consistent release of HIV, enforcing the 
hypothesis that the block of the superinfecting HIV may 
occur at a postretrotranscription step. 
293bp 
A 
X 
110bp 
FrG. 8. DNA-PCR of HIV-l-superinfected clones P2, 6, and 9. Twelve 
days after HIV-1 superinfection with 1.7 x 104 TCIDso/106 cells (left) 
and 6.8 x 103 TCIDso/106 cells (right), cells were lysed and DNA was 
amplified using HTLV-IIIB specific vif primers (Rather et aL, 1985) (A) 
able to discriminate between the endogenous F12/HIV and the superin- 
fecting genome and two human /~-globin primers (Saiki et aL, 1985) 
(B). Sequences of HTLV-IIIB specific vif primers are, '~orward" 5' TAGC 
ACACAAGTAGACCCTGAA 3 ' ;  " reverse"  5 'TGTCCATTCATT-  
GTGTGGCTCCC 3'; and probe 5' ATATCAAGCAGGACATAAC 3'. Nu- 
cleotides that allow to discriminate between HTLV-IIIB and the endoge- 
nous F12/HIV vif sequences are underscored. 
82 FEDERICO ET AL. 
TABLE 2 
RT VALUES AND HIV BACK-TITRATION IN C8166 CELLS OF SUPERNATANTS 
OF P2, 6, AND 9 CLONES TRANSFECTED WITH THE HIV-1 INFECTIOUS 
MOLECULAR CLONE pNL4-3 
P2 6 9 
Time 
p.t. a cpm ~ TCIDso c cpm TCID~o cpm TCIDso 
12 hr 4.8 Neg ~ 1.5 Neg 2.9 Neg 
18 hr 1.1 ND e 2.4 Neg 2.8 Neg 
36 hr 3.5 1.4 5.8 Neg 4.1 Neg 
42 hr 8.0 ND 5.7 ND 1.1 ND 
60 hr 47.0 2.4 11.6 Neg 6.6 Neg 
66 hr 35.2 ND 6.6 ND 4.8 ND 
4 days 113.3 2.5 19.2 Neg 13.3 Neg 
5 days 51.1 ND 3.2 ND 7.5 ND 
6 days 96.5 3.1 3.5 Neg 6.5 Neg 
7 days 288.6 ND 2.1 ND 7.1 ND 
8 days 72.3 2.4 2.1 Neg 4.9 Neg 
9 days 220.7 2.5 4.4 Neg 6.3 Neg 
p.t., post-transfection. 
b RT values (cpm/ml X 10 3) in supernatants of transfected clones. 
° Iog~o. 
Neg, undetectable virus yields. 
e ND, not done. 
DISCUSSION 
Involvement of the F12/HIV genome in homologous 
viral interference was first suggested by evidence that 
the F12 cells (an Hut-78 clone chronically infected by the 
nonproducer F12 HIV-1 variant) were resistant to HIV-1 
and HIV-2 superinfection (Federico et aL, 1989). 
Despite CD4 down-regulation, superinfecting HlVs 
were demonstrated to enter the F12 cells and to initiate 
the retrotranscription process (Taddeo et al., 1993). The 
inability to complete its cDNA strands was indicated as 
the cause of the HIV-superinfection block in F12 cells. 
However, the CD4 failure in the F12 cell membrane could 
influence, in some instances, the amount of viral RNA 
molecules actually entering the infected F12 cell popula- 
tion, thus partially masking the role of the F12/HIV in the 
interfering phenomenon. 
Conversely, cells where the F12/HIV genome is fully 
coexpressed with the CD4 HIV receptors could be a more 
useful model in order to establish if and how the F12/ 
HIV genome is able to protect the host cells from HIV 
superinfection. 
A partial inhibition of superinfecting HIV-1 has already 
been demonstrated in engineered CEM cells expressing 
the F12/HIV genome promoted by the murine Moloney 
leukemia virus (MLV) LTRs of the retroviral vector pLj 
(Federico etaL, 1993a, 1993b). This noncomplete protec- 
tion was most likely due to low expression level of the 
F12/HIV genome under the MLV LTRs control. 
By transfecting the complete F12/HIV genome in He- 
La CD4+ cells, cell clones highly expressing the F12/ 
HIV genome were obtained. Interestingly, no reduction 
of the HIV receptors was observed in F12/H IV expressing 
He-La CD4+ clones. At first glance, this appears in con- 
trast to both the already published data about CD4 down- 
regulation of HIV chronically infected cell lines and the 
already mentioned evidence that the presence of the 
same viral genome in Hut-78 cells is accompanied by 
the block of HIV receptor exposure. An intrinsic inability 
(possibly due to some genetic mutations present in the 
F12/HIV genome) (Carlini et al., 1992) of the F12/HIV 
genome to down-regulate the CD4 molecules could be 
hypothesized by proposing that the F12/HIV genome 
originally integrated in an Hut-78 celt clone already CD4 
down-regulated in some HIV-independent manner. How- 
ever, this would be in contrast to published evidence 
about a post-transcriptional mechanism (i.e., the corn- 
plexing of gp160, CD4, and vpu proteins in the Golgi 
apparatus) of CD4 down-regulation in HIV-infected cells 
(Willey et aL, 1992), in that no aminoacidic mutation with 
respect to replication-competent HIV vpu gene has been 
detected by sequencing the F12/HIV genome. We also 
cannot exclude that the mechanism of down-regulation 
demonstrated in lymphoblastoid cells does not also oc- 
cur in the epithelioid He-La cells, induced to CD4 produc- 
tion by genetic manipulations. 
In view of its unaltered CD4 pat-tern, the F12/HIV ex- 
pressing He-La CD4+ clones are a good model for test- 
ing the ability of the nonproducer F12/HIV to interfere 
with HIV superinfection. In fact, in contrast to the parental 
F12 cells, the presence of CD4 receptors could allow the 
superinfecting HIV to bind to a similar extent in F12/HIV- 
transfected as well as in control (P2) He-La CD4+ clones. 
Data about the HIV superinfection resistance of the 
F12/HIV He-La CD4+ clones strongly confirm that F12/ 
HIV expression may result in intracellular immunization 
via a phenomenon of homologous viral interference inde- 
pendent of the down-regulation of HIV receptors. 
A non-OD4 down-regulated HIV-2 chronically and pro- 
ductively infected cell clone, which, however, remains 
fully susceptible to HIV-1 superinfection, was isolated by 
Le Guern and Lew (1992). in addition, the ACH2 cell line, 
that possesses a single integrated copy of the replication 
competent LAI HIV-1 strain, can be superinfected by the 
RF HIV-1 strain (Kim et aL, 1993). Qn the contrary, F12/ 
HIV genome is (i) a stably nonproducer nondefective ge- 
nome and (ii) an interfering genome that, however, does 
not affect the HIV receptor exposition. 
Regarding the mechanism(s) of F12/HIV-induced ho- 
mologous interference, the lack of superinfecting HIV 
DNA (Fig. 8) 12 days p.i. at the highest m.e.i, of clone 9 
(as shown in Table 1, the clone was fully protected) sug- 
gests that clone 9 was "cured" of HIV superinfection. In 
clone 6, exposed to the highest m.o.i., the positivity of 
RT and DNA-PCR assays may be accounted for as fol- 
lows, either the superinfecting HIV genome is present in 
all cells (thus viewed as an intermediate level of protec- 
tion from superinfection) or the superinfecting virus is 
present only in a fraction of the cells (possibly due to 
the emergence of cell revertants sensitive to HIV). 
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In CD4 down-regulated F12 cells, a block of retrotran- 
scription was demonstrated as the key molecular event 
leading to the inhibition of replication of the superin- 
fecting HIV-1 and -2. DNA-PCR experiments performed 
a few hours after HIV-2 superinfection of F12/HIV-trans- 
duced He-La CD4+ clones indicate that HIV-2 was able 
to complete the retrotranscription of its genomic RNA 
even in the absence of sustained virus replication. DNA- 
PCR data shown in Fig. 7 demonstrate that no impairment 
of retrotranscription of the superinfecting HIV-2 takes 
place in F12/HIV expressing He-La CD4+ Cell clones. 
The scanning analysis of the DNA-PCR experiment (see 
legend of Fig. 7) indicates that greater amounts of HIV- 
2 LTR-gag amplification product were detected in clones 
6 and 9 with respect to the P2 control clone. This differ- 
ence may be due to the activity, in the F12/HIV express- 
ing He-La CD4+ clones, of the reverse transcriptase cod- 
ified by the F12 provirus that may, in some instances, 
facilitate the reverse transcription process of the superin- 
fecting HIV-2. Unfortunately, we were not able to dupli- 
oatethe same kind of DNA-PCR analysis in HIV-1 super- 
infected F12/HIV He-La CD4+ clones, due to the highly 
conserved sequences in LTR-gag-PBS regions of F12/ 
HIV genome with respect to the replication-competent 
mlVs-1 sequenced so far. 
When the pNL4-3 infectious HIV cDNA was used as 
the challenge HIV, the homologous interference against 
the superinfecting HIV did operate, even at times shortly 
after transfection. This indicates that events distal to the 
synthesis of the HIV proviral DNA also block the replica- 
tion of the transfected HIV genome. 
It is widely accepted that >50% of transfected cells of 
an adherent culture, such as F12/HIV He-La CD4+ cells 
under the experimental conditions described under Ma- 
terials and Methods, receive and express plasmids with- 
out the need for integration, which is a rarer, slower 
event. Thus, approximately one-half of the F12/HIV He- 
ts CD4+ cells were presumably transfected by, and ex- 
press, the pNL4-3 genome. Since neither significant RT 
p0sitivity nor viral rescue are detectable even several 
days post-transfection, it follows that the expression of 
thetransfected HtV-1 molecular clone pNL4-3 is strongly 
inhibited in all cells of clones 6 and 9 that carry the F12/ 
HIV genome (Table 2). However, in pNL4-3-transfected 
clones 6 and 9 we cannot formally exclude synthesis of 
undetectable amounts of HIV whose life cycle could be 
blocked at different steps in a second round of infection. 
This could explain the detection of syncytia in pNL4-3- 
transfected clones after cocultivation with HIV suscepti- 
ble OEMss cells shortly after transfection. 
RT positive values were obtained in pNL4-3 
transfeoted F12 cell supernatants after cocultivation with 
0EMss cells (Taddeo et aL, 1993). On the contrary, no 
HIV release was detectable when transfected F12 cells 
were not cocultivated (unpublished data). However, this 
result could be limited by the constitutive absence of 
0D4 mlV receptors in F12 cells. On the contrary, the block 
of HIV replication in pNL4-3 transfected He-La CD4+ 
clones, where the CD4 exposure was not influenced by 
the F12/HIV expression so that superinfecting HIV could 
penetrate and spread, could be considered a more signif- 
icant result. It is possible that when CEMss cells were 
added to both F12 and F12/HIV expressing He-La CD4+ 
pNL4-3-transfected cultures, HIV immature viral parti- 
cles, full-length DNA or RNA were, under these condi- 
tions, propagated through intracellular connections be- 
tween CEMss- and pNL4-3-transfected cells. Viral repli- 
cation may, therefore, initiate when one of these viral 
components penetrates an HIV susceptible cell. How- 
ever, back-titration experiments on the supernatants of 
both F12 and F12/HIV He-La CD4+ clones (Table 2) allow 
us to exclude, that a relevant number of HIV infectious 
particles are released after pNL4-3 transfection. 
In summary, the data here reported confirm the ability 
of the F12/HIV ge~qome to interfere with the life cycle 
of a superinfecting HIV. These results confirm evidence 
already reported for CD4 down-regulated F12 cells, ex- 
tending the conclusions to cells expressing CD4 HIV 
receptors. Different mechanisms seem to be involved in 
the two different F12/HIV expressing cells (i.e., F12 ver- 
sus He-La CD4+ cells). A cooperative effect due to both 
CD4 failure (with a consequently reduced viral entry load) 
and the action of some viral, viral-induced, or even cellu- 
lar factor(s), better expressed in lymphoblastoid cells 
than in epithelioid ones, could explain this difference. 
The data here reported indicate post-transcriptional 
event(s) involved in the block of superinfecting HIV, sup- 
porting the hypothesis that a F12/HIV specific product, 
possibly in cooperation with some cellular or virus-in- 
duced cellular product, could induce the homologous 
viral interference phenomenon. Similar effects in trans 
were already demonstrated for gag (Trono et al., 1989) 
and rev (Malim et al., 1992) mutants and for env products 
(Stevenson et al., 1988). 
The observed intracellular immunization is certainly a 
complex one, but may serve as a safe tool for a "gene 
therapy" approach. However, for any attempts in humans 
it is crucial to define which part(s) of F12/HIV genome is 
(are) involved in the viral interference, considering also 
the possibility that a combination of two or more genes 
could be necessary to block HIV superinfection. A molec- 
ular construct including such F12/HIV sequences pro- 
moted by non-LTR sequences could be, in the future, a 
useful tool for possible clinical applications. 
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